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Abstract
Marine fungi are species of fungi which live in estuaries environment and 
marine environment. These species are found in common habitat. Marine fungi 
are rich in antimicrobial compounds such as anthrones, cephalosporins, peptides, 
steroids. These compounds which are derived mainly focused in the area of anti-
inflammatory, anti-oxidant, anti-fungal, anti-microbial, anti-fouling activity. 
Bioactive terpene compounds are produced by marine fungi and marine derived 
fungi can produce sclerotides, trichoderins. Marine fungi have become the rich-
est sources of biologically active metabolites and structurally novel in the marine 
environment. In a recent study the marine derived fungi dichotomomyces cejpii 
exhibits activity towards cannabinoid which is used to treat alzheimer dementia. 
Aspergillus unguis showed significant acetyl cholinesterase besides its anti-oxidant 
activity. These acts as a promising intent for discovery of pharmaceutically impor-
tant metabolites like alkaloids, peptides. Computational (in silico) strategies have 
been developed and broadly applied to pharmacology advancement and testing. 
This review summarizes the bioactive compounds derived from marine fungi in 
accordance with the sources and their biological activities.
Keywords: marine fungi, bioactive compounds, docking, metabolites
1. Introduction
To date there are about 100,000 fungal species, it is expected about one million 
species that are to be present. In spite of the fact that assessments for the quantity 
of fungi around 1.5 to more than 5 million, likely less than 10% of fungi have been 
identified till date. Marine derived fungi are rich in new metabolites [1, 2]. Marine 
derived fungi consists of secondary metabolites which acts a promising pharma-
cological and biological properties [3]. Fungi are significant parasites of nutrient 
cyclers and primary producers. These are tremendously understudied in the marine 
domain and information on their function is obliged by the fungal dispersion and 
drivers on worldwide scales [4]. Marine fungi are significant source of secondary 
metabolites. Despite the fact that marine parasites are less investigated in contrast, 
various valuable hits have been acquired from the drug discovery point of view 
adding to their significance in the product discovery [5, 6]. Source of drugs isolated 
from fungi are being used as camptothecin, torreyanic corrosive, vincristine and 
cytarabine and paclitaxel. Drug resistance towards diseases like tuberculosis, cancer 
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and HIV-AIDS have been biological target with restricted accomplishment [7]. 
A few classes of particular metabolites from marine fungi have a wide scope of 
bio activities against various activities. From marine fungi, more than thousand 
metabolites have been accounted which can be possibly developed as drugs [8–10]. 
The source of these marine fungi metabolites is differed as their natural surround-
ings have been accounted from different sources, for example, algae, sponge, fungi 
and mangrove derived fungi from bottom residue [11]. Fungi can also be harnessed 
as sources of chemicals, food and biofuels when people exploit metabolism of fungi 
[12]. Secondary metabolites are produced by fungi for different purposes, including 
threat of different pathogens, iron chelation and microorganisms. These metabo-
lites have been recognized from EDF [13]. Isolation of fungi from marine samples 
has regularly led to the recuperation of microorganisms, which are morphologically, 
trophically and ecologically like fungi yet are false organisms [14]. Fungi are gener-
ally conveyed in marine conditions from intense ocean to polar ice covers. They are 
found in a wide range of dead and living organic matter. Fungi have been made with 
those related with sediments, with explicit substrates like algae, driftwood, corals 
and specifically with sponges [15]. Reliably, fungi confined from sponges represent 
the biggest number (28%) of novel compounds revealed from marine fungi [16]. 
In spite of the fact that bio activities of secondary metabolites from marine fungi 
unveil clinical targets; they are not well constituted for pipelines of drugs and none 
of them right now is available [17]. To date, in excess of 180 bioactive secondary 
metabolites got from deep ocean fungi have been reported. These natural metabo-
lites obtained are generally organic and compounds like Pencillium, Polyketides is 
largely discovered. These incorporate compounds with antimicrobial, anticancer, 
antiprotozoal, antifungal and antiviral activities [18]. Indeed, even in deep aque-
ous biological systems, an unsuspected high assorted variety of fungal species was 
discovered utilizing molecular approaches . At first samples are collected from 
the ocean. The next step is fungal cultures and sample preparation. In the lab, 
sterility was acquired by vertical laminar flow hood and bunsen burner. Cultures 
were allowed to grow aerobically at 25°C with atmospheric pressure and ambi-
ent temperature. GYPS medium is used for the growth of strains (1 g glucose, 1 g 
peptone, 1 g starch 1 g yeast and 30 g ocean salts). Then it is freeze-dried at 80°C. 
DNA is extracted by homogenizing each sample with sterile glass dabs at 30 rpm. 
DNA was removed from developed strains with a Fast DNA Spin pack. In Cloning 
and sequencing, the SSU rRNA qualities were amplified utilizing PCR (primers). 
Transfer DNA was amplified by PCR at 94°C for 1.30 minutes including 37 cycles of 
94°C for 30 s, followed by 48°C for 1.25 min, and 72°C for 1.5 min. The PCR ampli-
fication with a last extension step and performed at 72°C for 10 min. The fragments 
were refined with a High Pure PCR kit (Roche) furthermore, were cloned in the 
DH5 equipped cells and pGEM-T vector. The two strands was determined utilizing 
Sequencher 4.6 (GeneCodes), A different grouping arrangement was developed 
for every phylum utilizing Clustal X 1.81 containing all the databases. After this 
protocol, 1733 sequences from Basidiomycota,, 4117 sequences from Ascomycota, 
215 sequences from Chytridiomycota, 621 sequences from Glomeromycota and 292 
sequences from Zygomycota is obtained from various branches of phylogenetic 
fungal species. Every phylum was then exposed to a numerous grouping arrange-
ment methodology, trailed by neighbor-joining method. Phylogenetic trees were 
envisioned by utilizing Treeview. The phylogenetic neighbors nearest to the ecologi-
cal sequence were chosen, and afterward phylogenetic analysis were performed. A 
different sequence arrangement methodology was performed utilizing CLUSTALX 
1.81, and the arrangement was refined by eye. After these evaluation, phylotypes 
were indicated utilizing a cutoff of 98% (pairwise distance). Then qPCR analysis 
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were performed with 10-μl blends utilizing iQ SYBR green Supermix (Bio-Rad), 
which contained SYBR green PCR buffer, 2.7 μM dATP, 2.7 μM dGTP, 2.7 μM 
dCTP,2.7 μM dTTP, and 0.42 U of iTaq DNA polymerase (Bio-Rad). At that point 
0.35 μM preliminary MH2 (5′TTCGATGGTAGGATAG3′) and 0.35 μM primer 
FungqPCR1 (5′TGTCGGGATTGGGTAATTT3′) were added to the blend. Reactions 
were carried out in optical tubes and were fixed with microseal film. All reactions 
performed with Chromo 4 thermocycler, utilizing an underlying denaturation at 
94°C for 3 min to initiate the compound, trailed by 35 or 40 cycles of denaturation 
at 94°C for 30 s and furthermore expansion at 48°C for 45 s and afterward by plate 
perusing. The dissociation curve for temperatures from 65–95°C was estimated after 
the last qPCR cycle. All informations analyzed utilizing Opticon Monitor 3. Samples 
which showed the most grounded signals in two starter runs were compared at in a 
last run. Different plasmid concentrations were utilized to build a standard curve 
for supreme quantification. Using this formula, standards are found: molecules/
μl = a/(plasmid length × 660) × (6.022 × 10^23) where a is the plasmid of concen-
tration in (μg/μl), 6.022 × 10^23 -molar constant, 660- avaerage molecular weight 
of one base pair [19]. The greater part of the work on secondary metabolites of 
marine organisms has concentrated on genera, mainly Penicillium, Aspergillus and 
additionally Fusarium and Cladosporium, moreover the less contemplated species 
merit extraordinary consideration [20]. Biological activity can also be identified 
using In Silico methods. It gives fast predictions for a large set of compounds in a 
high-throughput mode. The aim of target discovery is the validation and identifica-
tion of suitable drug targets for therapeutic intervention and discovery of novel 
chemical molecules that acts on the most relevant targets for a disease under study. 
In silico methods include quantitative structure–activity relationships, databases, 
similarity searching, homology models, pharmacophores, and other molecular 
modeling, data mining, machine learning, data analysis and network analysis tools 
that use a computer. Such methods have seen frequent use in the discovery and 
optimization of physicochemical characterization [21, 22].
2. Secondary metabolites and bioactive compounds
Two new metabolites, carbonarones A (1) and B (2), were acquired from the 
marine-fungi Aspergillus carbonarius detached from the marine residue gathered 
at Weizhou island of China. It indicated moderate cytotoxicity against K562 cells 
with IC50 estimations of 56.0 and 27.8 μg/ml, individually [23]. 14-norpseurotin 
A, 29-nordammarane triterpenoid 6β show noteworthy antimicrobial activity 
against Bacillus subtilis, Escherichia coli and Micrococcus lysoleikticus with MICs of 
3.74, 14.97 μM [24]. From the fungi extracts Ascochyta heteromorpha, the agent 
of a foliar infection of oleander (Nertum oleander), another cytochalasin named 
ascochalasin was separated together with deoxaphomin and cytochalasins A and 
B. Cytochalasins are an enormous gathering of contagious metabolites created 
by a few genera of fungi which demonstrated diverse biological activities. These 
compound binds to actin filaments and block the polymerization and also involved 
in the elongation of actin [25–28]. Three new metabolites, microsphaeropsones A–C 
(1–3) with an interesting oxepino[2,3-b]chromen-6-one, were detached from the 
endophytic growth Microsphaeropsis species [29] (Figure 1).
A semisynthetic dihydrooxepino[2,3-b]chromen6-one 7 was set up by oxida-
tion of the allylic alcohol 1 with manganese dioxide [29]. Marine-derived fungi 
Aspergillus versicolor MF160003 for the pharmacologically dynamic secondary 
metabolites prompts the disclosure of another Xanthenone derivative, 3-hydroxy 
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pinselin, with five known compounds, pinselin,methyl 8-hydroxy-6-methyl-9-oxo-
9H-xanthene-1-carboxylate, 2-methoxy pinselin, aspergillusone A 12-O-acetyl-
AGI-B4 [30]. Screening for new bioactive metabolites from the marine-determined 
variety of Aspergillus, an Aspergillus versicolor DJ013 separated from a coastal, 
Dongji Island, China. EtOAc separate resulted in identification and isolation of new 
furandione compounds, named asperfurandiones A and B [31]. Botryosphaerin 
were detached from the endophytic fungi Botryosphaeria sp. MHF associated with 
Maytenus hookeri. A compound CJ-14445 showed inhibition towards Saccharomyces 
cervisiae, Candida albicans and Penicillium avellaneum UC-4376 in correlation with 
nystatin which was utilized as a positive control [32] (Figure 2).
2.1 Bioactivities
Xanalteric acids I (38) and II (39) are the two new compounds which were segre-
gated from the organism Alternaria sp., taken from leaves of the Mangrove plant 
Sonneratiaceae, gathered in Dong Zhai Gang Mangrove Garden on Hainan Island, 
China. Compounds 38 and 39 showed frail anti-microbial action against multidrug-
resistant S. aureus with MIC estimations of 686.81–343.40 μM [34]. Spicellum 
roseum yielded the equivalent trichothecene as is delivered by the Trichothecium 
roseum. The compound demonstrated antimicrobial properties against specific 
yeasts of Saccharomyces cerevisiae and Candida albicans [35]. The absolute num-
ber of lignin from chosen white, soft and brown rot fungi were isolated. These 
outcomes have uncovered that, most elevated ligninolytic capacity was seen in 
P. ostreatus, P. eryngii S. hirsutum (white rot fungi), C. puteana H. pinastri (brown 
Figure 1. 
Compounds 1–6 isolated from the endophytic fungus Microsphaeropsis sp. and 7 obtained by the oxidation of 1 [29].
Figure 2. 
Different types of fungal metabolites [33].
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rot fungi) F. oxysporum and B. dothidea (soft rot fungi) [36]. The fungi recognized 
as Neopestalotiopsis sp., active against D. phaseolorum. The outcomes feature that the 
endophytes are equipped for delivering compounds that might be utilized to control 
plant pathogens. The compound fumiquinone B is accounted for just because as an 
antifungal operator against D. phaseolorum, a significant plant pathogen around 
the world. This is additionally the first report of the production of fumiquinone B 
by the Neopestalotiopsis [37]. Fungi M. albus identified with Cinnamomum zeylani-
cum, recognized five classes of unstable compounds like alcohols, esters ketones, 
lipids and acids which smothered the action of pathogenic fungi, namely Pythium 
ultimum, Phytophthora cinnamomi Rhizoctonia solani, Ustilago hordei, A.fumigates, 
Stagnosporanodorum, Sclerotinia sclerotiorum, Tapesia yallundae, F. solani, Cercospora 
beticola, C. albicans and Verticillum dahlia [38]. The detached metabolite sclerotio-
rin from Cephalotheca faveolata had the capacity to incite apoptosis in malignant 
growth cells.
Sclerotiorin had apoptotic properties for colon malignant growth (HCT-116) 
cells by means of BAX and inactivated the BCL-2 proteins and further degrade 
the caspase-3 catalyst advancing apoptosis in dangerous cells [39]. Antibacterial 
action of the detached bioactive parts from endophytic growth Phomopsis sp. 
inside Plumeria acutifolia against the bacterial pathogens E. coli, Klebsilla sp 
Pseudomonas sp., S. aureus, B. subtilis also, S. typhi and it had no huge impact on 
C. albicans [40, 41]. Awajanoran, another dihydrobenzofuran derivative, was 
separated from an agar-culture of Acremonium sp. AWA16–1, which had been 
separated from ocean mud gathered at Awajishima Island in Japan. This com-
pound restrained the development of A549 cells, the human lung adenocarcinoma 
cell line, with an IC50 estimation of 17 μg/ml, and furthermore demonstrated 
antimicrobial action [42]. R-135853 against different contagious strains and 
furthermore shows the MICs of R-135853 forthe strains utilized in vivo. R-135853 
showed strong activity against C. albicans, C. tropicalis, C. glabrata, C. neoformans 
and C. guilliermondii with MICs varying from 0.016 to 0.5 g/ml [43].
3. Docking studies
A chain of 1-(1H-1,2,4-triazol-1-yl)- 2-(2,4-difluorophenyl)- 3-subbed 2-propanols 
(5a–5y) which are analogs of fluconazole, have been structured and integrated by 
means of Cu(I)- catalyzed azide–alkyne cycloaddition based on computational 
docking investigations to the dynamic site of the cytochrome P450 14α-demethylase 
Figure 3. 
Compounds binding geometry of the new inhibitor 5 l in the active site of CYP51 [44].
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(CYP51). Target compounds were assessed against eight human pathogenic fungi in 
vitro. Compound 5 l demonstrated the best antifungal activity [44] (Figure 3).
Tyrosol, extracted from P. chrysogenum DXY-1, a marine fungi utilized as a QS 
inhibitor against C. violaceum and P. aeruginosa. The docking results show that tyro-
sol hinders the QS system of CviR in C. violaceum by binding to the DNA-binding 
domain and blocking the gene expression of pathogens [45] (Figure 4).
Three compounds (heptadecanoic acid, 16 methyl-, methyl ester; 9,12-octa-
decadienoic acid; cis-9-octadecenoic corrosive) identified and were screened 
against the skin cancer protein (Hsp90) by in-silico docking. The metabolites in two 
fungal strains of Hypocrea species were analyzed in GC–MS and the compound 
(Heptadecanoic corrosive, 16 methyl) indicated the best outcome against skin 
cancer protein [46] (Figure 5).
A 3D model of the cytochrome P450 14a-sterol demethylase of C. albicans 
(CA-CYP51) was built on the premise of the sequence homology with structure 
of the cytochrome P450 14a-sterol demethylases of M. tuberculosis (MT-CYP51). 
The model of CA-CYP51 was utilized to clarify the antifungal movement of a chain 
of 1,4-benzothiazine and 1,4-benzoxazine imidazole derivatives. All compounds 
receive comparable binding modes inside the catalytic site of CA-CYP51. These 
outcomes will be used to address the structure and synthesis of new strong antifun-
gal compounds supplied with hostile to Candida action [47] (Figure 6).
Mannich bases of thiosemicarbazide is tested for anti-fungal activity. Docking 
of compounds was performed on the pdb structure of Lanosterol 14 α-demethylase 
(CYP51A1, P45014DM) utilizing Vlife MDS 3.5 as target. All incorporated atoms 
Figure 4. 
Effects of tyrosol on the growth of C. violaceum CV026 and violacein production in C. violaceum [45].
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Figure 5. 
GC–MS result of potential compound Heptadecanoic acid, 16 methyl derived from Hypocrea lixii TSK8 [46].
Figure 6. 
Best docking solution of fluconazole into the catalytic site of CA-CYP51 [47].
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were docked into a similar binding site. Docking study demonstrated a solid hydro-
phobicity between amino acids, such as Arganine (ARG141), Glutamine (GLU146), 
with hydrogen of aldehyde at 2.279. The amino acids included are Glycine GLY176A, 
Aspartine ASP175A, Threonine THR147B Lysine LYS227A, Phenyl alanine PHE58A 
and Arganine ARG141B which may be assuming a significant role in the specific 
binding of compounds with target [48] (Figure 7).
4. Recent discoveries
In this investigation, researchers scanned for new secondary metabolites from 
ocean inferred growth strain FKJ-0025 and found two new compounds, sarco-
podinols A (1) and B (2), together with a known compound, SF-227. This is the 
principal report of secondary metabolites separated from family Sarcopodium. 
Cytotoxicity test utilizing human tumor cell lines, 1 demonstrated cytotoxicity 
against Jurkat cells. Eminently, 2 demonstrated cytotoxicity against HL-60, Jurkat, 
and Panc1 cells. These outcomes recommend that the absence of 5′-OH is the 
significant factor behind the lethality against HL-60 and Panc1 cells [49]. The novel 
Anthraquinone, 2-(dimethoxymethyl)- 1-hydroxyanthracene-9,10-dione, jointly 
with nine studied compounds (2–10), were taken from a marine derived fungi A. 
versicolor. 1 showed solid inhibitory activity against MRSA ATCC 43300 and MRSA 
CGMCC 12409 (with MIC estimations of 3.9 and 7.8 μg/mL separately) and mod-
erate activity against analyzed strains of Vibrio. Molecular docking studies with 
Figure 7. 
Representative interactions shown by K20 with amino acid residues of CYP51A1, P45014DM [48].
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AmpC β-lactamase IV and topoisomerase indicated least binding interactions and 
supported antimicrobial movement of this compound is a novel compound merited 
expanding consideration as a source of antibacterial factor [50].
4.1 Antimicrobial agents
Antifungal peptides created by certain lactic acid bacteria strains have high 
potential for applications in expansive scope of nourishments. The component of 
peptides antifungal movement is identified with their properties, for example, 
low atomic weight, secondary structure, concentrations. The antifungal peptides 
were proposed to be utilized as bio-additives to decrease as well as supplant chemi-
cal preservatives [51]. White rot fungi that go under the division eumycota are 
heterogeneous gathering of fungi having ability to degrade a wide assortment of 
difficult compounds. Xenobiotic degradation may be due to non-specific enzymes. 
Manganese peroxidase, laccase, lignin peroxidase were explored seriously for the 
wide scope of xenobiotics. These organisms are having the ability to separate the 
lignin in wood without degrading cellulose, sometimes both cellulose and lignin 
will be degraded [52]. Nanotechnology for the creation of nanoparticles utilizing 
fungal cells is an ongoing phenomenon. Parasite like Colletotrichum sp., A. clavatus, 
and Pestalotia sp. have been utilized for improvement of nanoparticles against 
pathogenic microorganisms [33].
5. Conclusion
Bioinformatics has built up itself as a basic apparatus in target revelation. In 
silico pharmacology paradigm is progressing and presents a rich exhibit of chances 
that will help with expediating the revelation of new targets, and leads to discovery 
of compounds with biological activities. The drug design is based on analysis of 
structure of fungal species complexes. Various evaluations are found using quasi 
in vivo assay and pharmacokinetic analysis. For example, X-ray structures of C. 
albicans CYP51 complexes with posaconazole and VT-1161, providing a molecular 
mechanism for the potencies of these drugs against pathogens that are intrinsically 
resistant to fluconazole.
Future perspectives
Comparative structural analysis indicates the phylum-specific CYP51 features 
highlights that could coordinate future rational improvement of more produc-
tive expansive range antifungals. Basic assay normally focused on antimicrobial 
and antifungal activity. Viable and safe medications in the field on infections and 
malignant growth are unquestionably required. Subsequently, it is recommended 
to widen biological screens for the once in a while examined biological activities, 
which might be significant for the treatment of ceaseless illnesses.
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